TriSalus Life Sciences, Inc.
TLSI
$5.23
$0.010.19%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -55.45M | -54.54M | -64.18M | -59.23M | -46.27M |
| Total Depreciation and Amortization | 753.00K | 740.00K | 696.00K | 692.00K | 436.00K |
| Total Amortization of Deferred Charges | 434.00K | 267.00K | -- | -- | -- |
| Total Other Non-Cash Items | 16.31M | 6.26M | 12.06M | 7.68M | -3.91M |
| Change in Net Operating Assets | -6.04M | -7.52M | 810.00K | 610.00K | 24.00K |
| Cash from Operations | -43.99M | -54.80M | -50.61M | -50.25M | -49.71M |
| Capital Expenditure | -667.00K | -676.00K | -647.00K | -588.00K | -420.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.00M | -1.00M | -1.00M | -1.00M | -1.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 672.00K | -262.00K | -261.00K | -328.00K | -68.00K |
| Cash from Investing | -995.00K | -1.94M | -1.91M | -1.92M | -1.49M |
| Total Debt Issued | 25.00M | 25.00M | -- | -- | -- |
| Total Debt Repaid | -87.00K | -87.00K | -87.00K | -87.00K | -192.00K |
| Issuance of Common Stock | 12.69M | 6.87M | 3.28M | 179.00K | 115.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 0.00 | 4.51M | 10.92M | 18.82M | 24.83M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.61M | 33.13M | 35.72M | 35.72M | 35.74M |
| Cash from Financing | 34.99M | 69.42M | 49.83M | 54.63M | 60.49M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.00M | 12.68M | -2.70M | 2.46M | 9.30M |
